The potential association between postmenopausal hormone use and primary open-angle glaucoma

JAMA Ophthalmology

Volumn 132, Issue 3, 2014, Pages 298-303

  Newman Casey, Paula Anne ^a   Talwar, Nidhi ^a   Nan, Bin ^b   Musch, David C ^a,b   Pasquale, Louis R ^c,d   Stein, Joshua D ^a  

^a UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

^b UNIVERSITY OF MICHIGAN SCHOOL OF PUBLIC HEALTH   (United States)

^c HARVARD MEDICAL SCHOOL   (United States)

^d CHANNING LABORATORY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANDROGEN; ESTROGEN; PROGESTERONE;

ADULT; AGED; ARTICLE; COHORT ANALYSIS; DRUG USE; FEMALE; HORMONAL THERAPY; HUMAN; LONGITUDINAL STUDY; MEDICAL RECORD REVIEW; MIDDLE AGED; OPEN ANGLE GLAUCOMA; POSTMENOPAUSE; PRESCRIPTION; PRIORITY JOURNAL; RETROSPECTIVE STUDY; RISK FACTOR;

AGED; ANDROGENS; DRUG COMBINATIONS; DRUG PRESCRIPTIONS; ESTROGEN REPLACEMENT THERAPY; ESTROGENS; FEMALE; GLAUCOMA, OPEN-ANGLE; HUMANS; INCIDENCE; INTRAOCULAR PRESSURE; MANAGED CARE PROGRAMS; MIDDLE AGED; PROGESTERONE; PROPORTIONAL HAZARDS MODELS; RETROSPECTIVE STUDIES; RISK FACTORS; TONOMETRY, OCULAR; UNITED STATES;

EID: 84896271606     PISSN: 21686165     EISSN: None     Source Type: Journal    
DOI: 10.1001/jamaophthalmol.2013.7618     Document Type: Article

References (28)

1. Munaut C, Lambert V, Noël A, et al. Presence of oestrogen receptor type beta in human retina. Br J Ophthalmol. 2001;85(7):877-882. (Pubitemid 32662092)
2. Russo R, Cavaliere F,Watanabe C, et al. 17Beta-estradiol prevents retinal ganglion cell loss induced by acute rise of intraocular pressure in rat. Prog Brain Res. 2008;173:583-590.
3. Uncu G, Avci R, Uncu Y, Kaymaz C, Develioǧlu O. The effects of different hormone replacement therapy regimens on tear function, intraocular pressure and lens opacity. Gynecol Endocrinol. 2006;22(9):501-505. (Pubitemid 44657945)
4. Sator MO, Joura EA, Frigo P, et al. Hormone replacement therapy and intraocular pressure. Maturitas. 1997;28(1):55-58. (Pubitemid 27475585)
5. Affinito P, Di Spiezio Sardo A, Di Carlo C, et al. Effects of hormone replacement therapy on ocular function in postmenopause. Menopause. 2003;10(5):482-487.
6. Altintaş O, Caglar Y, Yüksel N, Demirci A, KarabaşL. The effects of menopause and hormone replacement therapy on quality and quantity of tear, intraocular pressure and ocular blood flow. Ophthalmologica. 2004;218(2):120-129. (Pubitemid 38344103)
7. Tint NL, Alexander P, Tint KM, Vasileiadis GT, Yeung AM, Azuara-Blanco A. Hormone therapy and intraocular pressure in nonglaucomatous eyes. Menopause. 2010;17(1):157-160.
8. Hulsman CA,Westendorp IC, Ramrattan RS, et al. Is open-angle glaucoma associated with early menopause? the Rotterdam Study. Am J Epidemiol. 2001;154(2):138-144. (Pubitemid 32643128)
9. Lee AJ,Mitchell P, Rochtchina E, Healey PR; Blue Mountains Eye Study. Female reproductive factors and open angle glaucoma: the Blue Mountains Eye Study. Br J Ophthalmol. 2003;87(11):1324-1328. (Pubitemid 37452552)
10. Pasquale LR, Rosner BA, Hankinson SE, Kang JH. Attributes of female reproductive aging and their relation to primary open-angle glaucoma: a prospective study. J Glaucoma. 2007;16(7): 598-605. (Pubitemid 350307611)
11. Rossouw JE, Anderson GL, Prentice RL, et al; Writing Group for theWomen's Health Initiative Investigators. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from theWomen's Health Initiative randomized controlled trial. JAMA. 2002;288(3):321-333. (Pubitemid 34761611)
12. Anderson GL, Limacher M, Assaf AR, et al Women's Health Initiative Steering Committee. Effects of conjugated equine estrogen in postmenopausal women with hysterectomy: the Women's Health Initiative randomized controlled trial. JAMA. 2004;291(14):1701-1712. (Pubitemid 38489892)
13. Menopausal Hormone Therapy for the Primary Prevention of Chronic Conditions. US Preventive Services Task Force website. 2012. http://www.uspreventiveservicestaskforce.org/uspstf/uspspmho.htm. Accessed January 15, 2014.
14. LaCroix AZ, Chlebowski RT, Manson JE, et al WHI Investigators. Health outcomes after stopping conjugated equine estrogens among postmenopausal women with prior hysterectomy: a randomized controlled trial. JAMA. 2011;305(13):1305-1314.
15. KumleM. Declining breast cancer incidence and decreased HRT use. Lancet. 2008;372(9639): 608-610.
16. Stein JD, Kim DS, Mundy KM, et al The association between glaucomatous and other causes of optic neuropathy and sleep apnea. Am J Ophthalmol. 2011;152(6):989-998.e3.
17. Newman-Casey PA, Talwar N, Nan B, Musch DC, Stein JD. The relationship between components of metabolic syndrome and open-angle glaucoma. Ophthalmology. 2011;118(7):1318-1326.
18. Stein JD, Kim DS, Niziol LM, et al. Differences in rates of glaucoma among Asian Americans and other racial groups, and among various Asian ethnic groups. Ophthalmology. 2011;118(6):1031-1037.
19. Muir KW, Gupta C, Gill P, Stein JD. Accuracy of International Classification of Diseases, Ninth Revision, Clinical Modification billing codes for common ophthalmic conditions. JAMA Ophthalmol. 2013;131(1):119-120.
20. Hosmer DW, Jovanovic B, Lemeshow S. Best subsets logistic regression. Biometrics. 1989;45(4):1265-1270. (Pubitemid 20085469)
21. CharlsonME, Pompei P, Ales KL, MacKenzie CR. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis. 1987;40(5):373-383. (Pubitemid 17055592)
22. Doshi V, Ying-Lai M, Azen SP, Varma R. Sociodemographic, family history, and lifestyle risk factors for open-angle glaucoma and ocular hypertension: the Los Angeles Latino Eye Study. Ophthalmology. 2008;115(4):639-647.e2.
23. Dielemans I, Vingerling JR,Wolfs RC, Hofman A, Grobbee DE, de Jong PT. The prevalence of primary open-angle glaucoma in a population-based study in the Netherlands: the Rotterdam Study. Ophthalmology. 1994;101(11):1851-1855. (Pubitemid 24378870)
24. Kang JH, Wiggs JL, Rosner BA, et al. Endothelial nitric oxide synthase gene variants and primary open-angle glaucoma: interactions with sex and postmenopausal hormone use. Invest Ophthalmol Vis Sci. 2010;51(2):971-979.
25. Scott E, Zhang QG,Wang R, Vadlamudi R, Brann D. Estrogen neuroprotection and the critical period hypothesis. Front Neuroendocrinol. 2012;33(1):85-104.
26. RoccaWA, Grossardt BR, Shuster LT. Oophorectomy, menopause, estrogen treatment, and cognitive aging: clinical evidence for a window of opportunity. Brain Res. 2011;1379:188-198.
27. Pike CJ, Carroll JC, Rosario ER, Barron AM. Protective actions of sex steroid hormones in Alzheimer's disease. Front Neuroendocrinol. 2009;30(2):239-258.
28. MacLennan AH, Henderson VW, Paine BJ, et al. Hormone therapy, timing of initiation, and cognition in women aged older than 60 years: the REMEMBER pilot study. Menopause. 2006;13(1):28-36.